Virtu Financial LLC Bio Line Rx Ltd. Transaction History

Virtu Financial LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 26, 2024	BUY	$1.31 - $1.86 $9,331 - $13,248	7,123 Added 30.67%	30,351 $48,000
Q3 2023 Nov 14, 2023	BUY	$1.23 - $2.45 $14,370 - $28,623	11,683 Added 101.2%	23,228 $42,000
Q2 2023 Jul 27, 2023	BUY	$0.96 - $1.78 $11,083 - $20,550	11,545 New	11,545 $18,000
Q3 2022 Nov 07, 2022	BUY	$0.88 - $1.91 $26,884 - $58,352	30,551 Added 195.63%	46,168 $43,000
Q2 2022 Aug 09, 2022	BUY	$1.06 - $1.82 $16,554 - $28,422	15,617 New	15,617 $20,000
Q3 2021 Nov 12, 2021	SELL	$2.65 - $3.35 $43,931 - $55,536	-16,578 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$2.63 - $4.88 $43,600 - $80,900	16,578 New	16,578 $47,000

3.3M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $29.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.